2014

After the ownership changes have been realised within hameln pharmaceuticals gmbh and hameln rds gmbh, today we are a part of hameln group with following companies:

hameln-1

  • Specialised in marketing of products for acute treatments
  • Germany based office

hameln-2

  • Specialised in marketing of products for acute treatments
  • UK based office

hameln-3

  • Development and all health care market services with location in Slovakia

2007

Name of the company has been changed into hameln rds a.s

2006

Acquisition of 100% shares of VULM a.s. by hameln rds gmbh

1996

Transformation of the Drug Research Institute, š.p., (state enterprise) into VULM, a.s. (joint-stock company) with approximately 165 employees. Slovakofarma, a.s. became the main shareholder having 51% of the equity

1991

The Section of Biological research and the Section of Analytical Chemistry were awarded with the Certificate of Good Laboratory Praxis (GLP). The Institute became a first organisation obtaining GLP Certificate in Slovakia

1989

Finishing of the construction of new buildings in Modra and organisation of the official opening ceremony. At this time, Institute had 395 employees

1977

Decision of the Ministry of Health to move the main seat of the Institute from Hlohovec to Modra

1972

Foundation of the Drug Research Institute as an independent Institution of Spofa having its office location in Hlohovec with 54 employees